Vitamin D pp 393-409 | Cite as

Chemotherapeutic and Chemopreventive Actions of Vitamin D3 Metabolites and Analogs

  • Thomas A. Brasitus
  • Marc Bissonnette
Chapter
Part of the Nutrition and Health book series (NH)

Abstract

Over the past 15 years, a number of exciting developments have occurred in the vitamin D field, including the discovery of new target tissues, elucidation of novel mechanisms of action, and the synthesis of analogs of vitamin D3, which, in general, are more potent and selective in their actions than naturally occurring active metabolites of vitamin D3 (1). These developments have in turn generated great interest in the potential use of vitamin D-related compounds to treat and/or prevent a number of pathologic conditions, including malignant transformation in a variety of organs.

Keywords

Malignant Cell Line Monocytic Differentiation Human Myeloid Leukemia Cell Supplemental Dietary Calcium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bilde DD. Vitamin D: New actions, new analogs, new therapeutic potential. Endocrinol Rev 1992; 13: 765–784.Google Scholar
  2. 2.
    Minghetti PP, Norman AW. 1,25(OH)2-vitamin D3 receptors: gene regulation and genetic circuitry. FASEB J 1988; 2: 3043–3053.PubMedGoogle Scholar
  3. 3.
    Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992; 13: 719–763.PubMedGoogle Scholar
  4. 4.
    Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JPM. Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol 1990; 37: 873–876.PubMedCrossRefGoogle Scholar
  5. 5.
    Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, Suda T. 1 a,25- Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981; 102: 937–943.PubMedCrossRefGoogle Scholar
  6. 6.
    Inaba M, Okuno S, Koyama H, Nishizawa Y, Morii H. Dibutyryl cAMP enhances the effect of 1,25dihydroxyvitamin D3 on a human promyelocytic leukemia cell, HL-60, at both the receptor and the postreceptor steps. Arch Biochem Biophys 1992; 293: 181–186.PubMedCrossRefGoogle Scholar
  7. 7.
    Kuribayashi T, Tanaka H, Abe E, Suda T. Functional defect of variant clones of a human myeloid leukemia cell line (HL-60) resistant to 1 a, 25-dihydroxyvitamin D3. Endocrinology 1983; 113: 1992–1998.PubMedCrossRefGoogle Scholar
  8. 8.
    Ostrem VK, Lau WF, Lee SH, Perlman K, Prahl J, Schnoes HK, DeLuca HF, Ikekawa N. Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs. J Biol Chem 1987; 262:14, 164–14, 171.Google Scholar
  9. 9.
    Feldman J, Federico MHH, Sonohara S, Katayama MLH, Koike MAA, Roela RA, Da Silva MRP, Brentani MM. Vitamin D3 binding activity during leukemic cell differentiation. Leuk Res 1993; 17: 97–101.PubMedCrossRefGoogle Scholar
  10. 10.
    Dokoh S, Donaldson CA, Haussler MR. Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor. Cancer Res 1984; 44: 2103–2109.PubMedGoogle Scholar
  11. 11.
    Kawa S, Yoshizawa K, Tokoo M, Imai H, Oguchi H, Kiyosawa K, Homma T, Nikaido T, Furihata K. Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 1996; 110: 1605–1613.PubMedCrossRefGoogle Scholar
  12. 12.
    Bhatia M, Kirkland JB, Meckling-Gill KA. Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J Biol Chem 1995; 270:15, 962–15, 965.Google Scholar
  13. 13.
    Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. 1 a,25-Dihydroxy-16-ene-23-yne26,27-hexafluorocholecalciferol (R024–5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994; 54: 1653–1656.PubMedGoogle Scholar
  14. 14.
    Norman AW, Sergeev IN, Bishop JE, Okamura WH. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues. Cancer Res 1993; 53: 3935–3942.PubMedGoogle Scholar
  15. 15.
    Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980; 9: 227–231.PubMedCrossRefGoogle Scholar
  16. 16.
    Emerson JC, Weiss NS. Colorectal cancer and solar radiation. Cancer Causes Control 1992; 3: 95–99.PubMedCrossRefGoogle Scholar
  17. 17.
    Gorham ED, Garland CF, Garland FC. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can J Public Health 1989; 80: 96–100.PubMedGoogle Scholar
  18. 18.
    Muir C, Waterhouse J, Mack T. Cancer Incidence in Five Continents, vol 5. IARC Scientific Publication No. 88. Lyon: International Agency for Research on Cancer, 1987.Google Scholar
  19. 19.
    Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19 year prospective study in men. Lancet 1985; 1: 307–309.PubMedCrossRefGoogle Scholar
  20. 20.
    Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176–1178.PubMedCrossRefGoogle Scholar
  21. 21.
    Bostick RM, Potter JD, Sellers TA, McKenzie DR, Kushi LH, Folsom AR. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. Am J Epidemiol 1993; 137: 1302–1317.PubMedGoogle Scholar
  22. 22.
    Kampman E, Giovannucci E, van’t Veer P, Rimm E, Stampfer MJ, Colditz GA, Kok FJ, Willett WC. Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol 1994; 139: 16–29.PubMedGoogle Scholar
  23. 23.
    Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Colon cancer and serum vitamin D metabolite levels 10–17 years prior to diagnosis. Am J Epidemiol 1995; 142: 608–611.PubMedGoogle Scholar
  24. 24.
    Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 1990; 10: 1307–1312.PubMedGoogle Scholar
  25. 25.
    Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prey Med 1990; 19: 614–622.CrossRefGoogle Scholar
  26. 26.
    Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP. 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995; 55: 2822–2830.PubMedGoogle Scholar
  27. 27.
    Frampton RJ, Osmond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res 1983; 43: 4443–4447.PubMedGoogle Scholar
  28. 28.
    Koga M, Eisman JA, Sutherland RL. Regulation of epidermal growth factor receptor levels by 1,25dihydroxyvitamin D3 in human breast cancer cells. Cancer Res 1988; 48: 2734–2739.PubMedGoogle Scholar
  29. 29.
    Saez S, Falette N, Guillot C, Meggouh F, Lefebvre M-F, Crepin M. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat 1993; 27: 69–81.PubMedCrossRefGoogle Scholar
  30. 30.
    Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952–1960.PubMedCrossRefGoogle Scholar
  31. 31.
    Halline AG, Davidson NO, Skarosi SF, Sitrin MD, Tietze C, Alpers DH, Brasitus TA. Effects of 1,25-dihydroxyvitamin D3 on proliferation and differentiation of CaCo-2 cells. Endocrinology 1994; 134: 710–1717.CrossRefGoogle Scholar
  32. 32.
    Cross HS, Hulla W, Tong W-M, Peterlik M. Growth regulation of human colon adenocarcinomaderived cells by calcium, vitamin D and epidermal growth factor. J Nutr 1995; 125: 20045–2008S.Google Scholar
  33. 33.
    Wargovich MJ, Lointier PH. Calcium and vitamin D modulate mouse colon epithelial proliferation and growth characteristics of a human colon tumor cell line. Can J Physiol Pharm 1987; 65: 472–477.CrossRefGoogle Scholar
  34. 34.
    Lointier P, Wargovich MJ, Saez S, Levin B, Wildrick DM, Boman BM. The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res 1987; 7: 817–821.PubMedGoogle Scholar
  35. 35.
    Niendorf A, Arps H, Dietel M. Effect of 1,25-dihydroxyvitamin D3 on human cancer cells in vitro. J Steroid Biochem 1987; 27: 825–828.PubMedCrossRefGoogle Scholar
  36. 36.
    Masuda S, Byford V, Kremer R, Makin HLJ, Kubodera N, Nishii Y, Okazaki A, Okano T, Kobayashi T, Jones G. In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines. J Biol Chem 1996; 271: 8700–8708.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhou JY, Norman AW, Chen D-L, Sun G-W, Uskokovic M, Koeffler HP. 1,25-Dihydroxy-16-ene23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 1990; 87: 3929–3932.PubMedCrossRefGoogle Scholar
  38. 38.
    Pols HA, Birkenhager JC, van Leeuwen JPTM. Vitamin D analogues: from molecule to clinical application. Clin Endocrinol 1994; 40: 285–292.CrossRefGoogle Scholar
  39. 39.
    Bouillon R, Allewaert K, van Leeuwen JPTM, Tan BK, Xiang DZ, De Clercq P, Vandewalle M, Pols HA, Bos MP, Van Baelen H, Birkenhager JC. Structure function analysis of vitamin D analogs with C-ring modifications. J Biol Chem 1992; 267: 3044–3051.PubMedGoogle Scholar
  40. 40.
    Dilworth FJ, Calverley MJ, Makin HL, Jones G. Increased biological activity of 20-epi-1,25dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. Biochem Pharm 1994; 47: 987–993.PubMedCrossRefGoogle Scholar
  41. 41.
    Bouillon R, Allewaert K, Xiang DZ, Tan BK, van Baelen H. Vitamin D analogs with low affinity for the vitamin D binding protein• enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991; 6: 1051–1057.PubMedCrossRefGoogle Scholar
  42. 42.
    Brown AJ, Dusso A, Slatopolsky E. Selective vitamin D analogs and their therapeutic applications. Semin Nephrol 1994; 14: 156–174.PubMedGoogle Scholar
  43. 43.
    Wali RK, Bissonnette M, Khare S, Hart J, Sitrin MD, Brasitus TA. 1a,25-Dihydroxy-16-ene-23yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 a,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 1995; 55: 3050–3054.PubMedGoogle Scholar
  44. 44.
    Cheskis B, Lemon BD, Uskokovic M, Lomedico PT, Freedman LP. Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25dihydroxyvitamin D3. Mol Endocrinol 1995; 9: 1814–1824.PubMedCrossRefGoogle Scholar
  45. 45.
    Haussler MR, Jurutka PW, Hsieh J-C, Thompson PD, Selznick SH, Haussler CK, Whitfield GK. Receptor mediated genomic actions of 1,25(OH)2D3: modulation by phosphorylation. In: Vitamin D. Norman AW, Bouillon R, Thomasset M, eds. New York: Walter de Gruyter, 1994; 209–216.Google Scholar
  46. 46.
    Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, Shintaku IP, Krajewski S, Reed JC, Binderup L, Koeffler HP. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996; 56: 3570–3576.PubMedGoogle Scholar
  47. 47.
    Vandewalle B, Hornez L, Wattez N, Revillion F, Lefebvre J. Vitamin-D3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer 1995; 61: 806–811.PubMedCrossRefGoogle Scholar
  48. 48.
    Hansen CM, Frandsen TL, Brunner N, Binderup L. la,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metast 1994; 12: 195–202.CrossRefGoogle Scholar
  49. 49.
    Skarosi S, Abraham C, Bissonnette M, Scaglione-Sewell B, Sitrin MD, Brasitus TA. 1,25-Dihydroxyvitamin D3 stimulates apoptosis in CaCo-2 cells. Gastroenterology 1997; 112: A608.Google Scholar
  50. 50.
    Jacobson EA, James KA, Newmark HL, Carroll KK. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12- dimethylbenz(a)-anthracene in female Sprague-Dawley rats. Cancer Res 1989; 49: 6300–6303.PubMedGoogle Scholar
  51. 51.
    Abe E, Miyaura C, Sakagami H, Takenda M, Konno K, Yamazaki T, Yoshiki S, Suda T. Differentiation of mouse myeloid leukemia cells induced by la,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981; 78: 4990–4994.PubMedCrossRefGoogle Scholar
  52. 52.
    Wood AW, Chang RL, Huang MT, Uskokovic M, Conney AH. 1 a, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 1983; 116: 605–611.PubMedCrossRefGoogle Scholar
  53. 53.
    Wood AW, Chang RL, Huang MT, Baggiolini E, Partridge JJ, Uskokovic M, Conney AH. Stimulatory effect of la, 25-dihydroxyvitamin D3 on the formation of skin tumors in mice treated chronically with 7,12-dimethylbenz[a]anthracene. Biochem Biophys Res Commun 1985; 130: 924–931.PubMedCrossRefGoogle Scholar
  54. 54.
    Kawaura A, Tanida N, Sawada K, Oda M, Shimoyama T. Supplemental administration of lahydroxyvitamin D3 inhibits promotion by intrarectal instillation of lithocholic acid in N-methyl-Nnitrosourea-induced colonic tumorigenesis in rats. Carcinogenesis 1989; 10: 647–649.PubMedCrossRefGoogle Scholar
  55. 55.
    Kawaura A, Takahashi A, Tanida N, Oda M, Sawada K, Sawada Y, Maekawa S, Shimoyama T. lahydroxyvitamin D3 suppresses colonic tumorigenesis induced by repetitive intrarectal injection of N-methyl-N-nitrosourea in rats. Cancer Lett 1990; 55: 149–152.PubMedCrossRefGoogle Scholar
  56. 56.
    Pence BC, Buddingh F. Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3. Carcinogenesis 1988; 9: 187–190.PubMedCrossRefGoogle Scholar
  57. 57.
    Corner PF, Clark TD, Glauert HP. Effect of dietary vitamin D3 (cholecalciferol) on colon carcinogenesis induced by 1,2-dimethylhydrazine in male Fischer 344 rats. Nutr Cancer 1993; 19: 113–124.CrossRefGoogle Scholar
  58. 58.
    Otoshi T, Iwata H, Kitano M, Nishizawa Y, Morii H, Yam Y, Otani S, Fukushima S. Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of la, 25-dihydroxyvitamin D3. Carcinogenesis 1995; 16: 2091–2097.PubMedCrossRefGoogle Scholar
  59. 59.
    Sitrin MD, Halline AG, Abrahams C, Brasitus TA. Dietary calcium and vitamin D modulate 1,2dimethylhydrazine-induced colonic carcinogenesis in the rat. Cancer Res 1991; 51: 5608–5613.PubMedGoogle Scholar
  60. 60.
    Llor X, Jacoby RF, Teng BB, Davidson NO, Sitrin MD, Brasitus TA. K-ras mutations in 1,2dimethylhydrazine-induced colonic tumors: effects of supplemental dietary calcium and vitamin D deficiency. Cancer Res 1991; 51: 4305–4309.PubMedGoogle Scholar
  61. 61.
    Belleli A, Shany S, Levy J, Guberman R, Lamprecht SA. A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis 1992; 13: 2293–2298.PubMedCrossRefGoogle Scholar
  62. 62.
    Thomas MG, Tebbutt S, Williamson RCN. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 1992; 33: 1660–1663.PubMedCrossRefGoogle Scholar
  63. 63.
    Lointier P, Meggouh F, Dechelotte P, Pezet D, Ferrier C, Chipponi J, Saez S. 1,25-Dihydroxyvitamin D3 receptors and human colon adenocarcinoma. Br J Surg 1991; 78: 435–439.PubMedCrossRefGoogle Scholar
  64. 64.
    Meggouh F, Lointier P, Pezet D, Saez S. Evidence of 1,25-dihydroxyvitamin D3-receptors in human digestive mucosa and carcinoma tissue biopsies taken at different levels of the digestive tract in 152 patients. J Steroid Biochem 1990; 36: 143–147.PubMedCrossRefGoogle Scholar
  65. 65.
    Lointier P, Meggouh F, Pezet D, Dapoigny M, Dieng PND, Saez S, Chipponi J. Specific receptors for 1,25-dihydroxyvitamin D3 (1,25-DR) and human colorectal carcinogenesis. Anticancer Res 1989; 9: 1921–1924.PubMedGoogle Scholar
  66. 66.
    Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res 1991; 51: 1227–1233.PubMedGoogle Scholar
  67. 67.
    Sandgren M, Danforth L, Plasse TF, DeLuca HF. 1,25-Dihydroxyvitamin D3 receptors in human carcinomas: a pilot study. Cancer Res 1991; 51: 2021–2024.PubMedGoogle Scholar
  68. 68.
    Kane KF, Langman MJ, Williams GR. 1,25-Dihydroxyvitamin D3 and retinoid X receptor expression in human colorectal neoplasms. Gut 1995; 36: 255–258.PubMedCrossRefGoogle Scholar
  69. 69.
    Bower M, Colston KW, Stein RC, Hedley A, Gazet J-C, Ford HT, Combes RC. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991; 337: 701, 702.Google Scholar
  70. 70.
    Godyn JJ, Xu H, Zhang F, Kolla S, Studzinski GP. A dual block to cell cycle progression in HL60 cells exposed to analogues of vitamin D3. Cell Prolif 1994; 27: 37–46.PubMedCrossRefGoogle Scholar
  71. 71.
    Rigby WF, Noelle RJ, Krause K, Fanger MW. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J Immunol 1985; 135: 2279–2286.PubMedGoogle Scholar
  72. 72.
    Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996; 56: 264–267.PubMedGoogle Scholar
  73. 73.
    Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25- Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984; 98: 391–398.PubMedCrossRefGoogle Scholar
  74. 74.
    Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74.PubMedCrossRefGoogle Scholar
  75. 75.
    Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993; 259: 1908–1912.PubMedCrossRefGoogle Scholar
  76. 76.
    Wang QM, Luo X, Studzinski GP. Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res 1997; 57: 2851–2855.PubMedGoogle Scholar
  77. 77.
    Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995; 55: 4623–4626.PubMedGoogle Scholar
  78. 78.
    Beno DWA, Brady LM, Bissonnette M, Davis BH. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated egr induction. J Biol Chem 1995; 270: 3642–3647.PubMedCrossRefGoogle Scholar
  79. 79.
    Kolch W, Heldecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marmé D, Rapp UR. Protein kinase C a activates RAF-1 by direct phosphorylation. Nature (Lond) 1993; 364: 249–252.CrossRefGoogle Scholar
  80. 80.
    Belka C, Wiegmann K, Adam D, Holland R, Neuloh M, Herrmann F, Kronke M, Brach MA. Tumor necrosis factor (TNF)-a activates c-raf-1 kinase via the p55 TNF receptor engaging neutral sphingomyelinase. EMBO J 1995; 14: 1156–1165.PubMedGoogle Scholar
  81. 81.
    Okazaki T, Bell RM, Hannun YA. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 1989; 264:19, 076–19, 080.Google Scholar
  82. 82.
    Bissonnette M, Tien X-Y, Niedziela SM, Hartmann SC, Frawley BP, Jr., Roy HK, Sitrin MD, Perlman RL, Brasitus TA. 1,25(OH)2 vitamin D3 activates PKC-a in CaCo-2 cells: a mechanism to limit secosteroid-induced rise in [Ca2+]. Am J Physiol 1994; 30: G465–6475.Google Scholar
  83. 83.
    Frey MR, Zhao X, Evans SS, Black JD. Activation of protein kinase C (PKC) isozymes inhibits cell cycle progression, modulates phosphorylation of the retinoblastomas (Rb) protein, and induces expression of p21wafl/c’pl in intestinal epithelial cells. Proc Am Assoc Cancer Res 1996; 37: 51.Google Scholar
  84. 84.
    Bissonnette M, Wali RK, Hartmann SC, Niedziela SM, Roy HK, Tien X-Y, Sitrin MD, Brasitus TA. 1,25-Dihydroxyvitamin D3 and 12–0-tetradecanol phorbol 13-acetate cause differential activation of Cat+-dependent and Cat+-independent isoforms of protein kinase C in rat colonocytes. J Clin Invest 1995; 95: 2215–2221.PubMedCrossRefGoogle Scholar
  85. 85.
    Wali RK, Bissonnette M, Starvarkos J, Sitrin MD, Brasitus TA. 1,25(OH)2D3 causes persistent activation of PKC-1311 in rat colonocytes and increases the baso-lateral membrane association of this isoform. Gastroenterology 1996; 110: A1131.Google Scholar
  86. 86.
    Murray NR, Baumgardner GP, Burns DJ, Fields AP. Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that (311 protein kinase C is required for proliferation. J Biol Chem 1993; 268:15, 847–15, 853.Google Scholar
  87. 87.
    Goss VL, Hocevar BA, Thompson LJ, Stratton CA, Burns DJ, Fields AP. Identification of nuclear 1311 protein kinase C as a mitotic lamin kinase. J Biol Chem 1994; 269:19, 074–19, 080.Google Scholar
  88. 88.
    Wali R, Bissonnette M, Khare S, Aquino B, Niedziela S, Sitrin M, Brasitus T. Protein kinase C isoforms in the chemopreventive effects of a novel vitamin D3 analogue in rat colonic tumorigenesis. Gastroenterology 1996; 111: 118–126.PubMedCrossRefGoogle Scholar
  89. 89.
    Wali RK, Frawley BP Jr, Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, Earnest DL, Sitrin MD, Brasitus TA, Bissonnette M. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-a, -1311, and -C. Cancer Res 1995; 55: 5257–5264.PubMedGoogle Scholar
  90. 90.
    Roy HK, Bissonnette M, Frawley BP, Jr., Wali RK, Niedziela SM, Earnest D, Brasitus TA. Selective preservation of protein kinase C-C in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. FEBS Lett 1995; 366: 143–145.PubMedCrossRefGoogle Scholar
  91. 91.
    Dominguez I, Diaz-Meco MT, Municio MM, Berra E, DE Herreros AG, Cornet ME, Sanz L, Moscat J. Evidence for a role of protein kinase C C subspecies in maturation of Xenopus laevis oocytes. Mol Cell Biol 1992; 12: 3776–3783.PubMedGoogle Scholar
  92. 92.
    Nakanishi H, Brewer KA, Exton JH. Activation of the C isoform of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1993; 268: 13–16.PubMedGoogle Scholar
  93. 93.
    Diaz-Meco MT, Lozano J, Municio MM, Berra E, Frutos S, Sanz L, Moscat J. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C C. J Biol Chem 1994; 269:31, 706–13, 710.Google Scholar
  94. 94.
    Diaz-Meco MT, Berra E, Municio MM, Sanz L, Lozano J, Dominguez I, Diaz-Golpe V, Lain de Lera MT, Alcami J, Paya CV, Arenzana-Seisdedos F, Virelizier J-L, Moscat J. A dominant negative protein kinase C Ç subspecies blocks NF-KB activation. Mol Cell Biol 1993; 13: 4770–4775.PubMedGoogle Scholar
  95. 95.
    Ways DK, Posekany K, deVente J, Garns T, Chen J, Hooker J, Qin W, Cook P, Fletcher D, Parker P. Overexpression of protein kinase C-Ç stimulates leukemic cell differentiation. Cell Growth Differ 1994; 5: 1195–1203.PubMedGoogle Scholar
  96. 96.
    Wooten MW, Zhou G, Seibenhener ML, Coleman ES. A role for Ç protein kinase C in nerve growth factor-induced differentiation of PC 12 cells. Cell Growth Differ 1994; 5: 395–403.PubMedGoogle Scholar
  97. 97.
    Levy R, Nathan I, Chaimovitz C, Shany S. The involvement of calcium ions in the effect of 1,25dihydroxyvitamin D3 on HL-60 cells. In: Current Advances in Skeletogenesis. Hurvits S, Sela J, eds. Jerusalem: Heiliger, 1987; 240–249.Google Scholar
  98. 98.
    Levy R, Nathan I, Barnea E, Chaimovitz C, Shany S. The involvement of calcium ions in the effect of 1,25-dihydroxyvitamin D3 on HL-60 cells. Exp Hematatol 1988; 16: 290–294.Google Scholar
  99. 99.
    Hazav P, Shany S, Moran A, Levy R. Involvement of intracellular pH elevation in the effect of 1,25dihydroxyvitamin D3 on HL-60 cells. Cancer Res 1989; 49: 72–75.PubMedGoogle Scholar
  100. 100.
    Brelvi ZS, Studzinski GP. Inhibition of DNA synthesis by an inducer of differentiation of leukemic cells, la,25 dihydroxyvitamin D3, precedes down regulation of the c-myc gene. J Cell Physiol 1986; 128: 171–179.PubMedCrossRefGoogle Scholar
  101. 101.
    Brelvi ZS, Christakos S, Studzinski GP. Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Lab Invest 1986; 55: 269–275.PubMedGoogle Scholar
  102. 102.
    Obeid LM, Okazaki T, Karolak LA, Hannun YA. Transcriptional regulation of protein kinase C by 1,25-dihydroxyvitamin D3 in HL-60 cells. J Biol Chem 1990; 265: 2370–2374.PubMedGoogle Scholar
  103. 103.
    Simpson RU, Hsu T, Begley DA, Mitchell BS, Alizadeh BN. Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. J Biol Chem 1987; 262: 4104–4108.PubMedGoogle Scholar
  104. 104.
    Solomon DH, O’Driscoll K, Sosne G, Weinstein IB, Cayre YE. la,25-dihydroxyvitamin D3-induced regulation of protein kinase C gene expression during HL-60 cell differentiation. Cell Growth Differ 1991; 2: 187–194.PubMedGoogle Scholar
  105. 105.
    Gartel AL, Serfas MS, Tyner AL. p21-negative regulation of the cell cycle. Proc Soc Exp Biol Med 1996; 213: 138–149.PubMedGoogle Scholar
  106. 106.
    Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142–153.PubMedCrossRefGoogle Scholar
  107. 107.
    Xu H-M, Tepper CG, Jones JB, Fernandez CE, Studzinski GP. 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Exp Cell Res 1993; 209: 367–374.PubMedCrossRefGoogle Scholar
  108. 108.
    Oberg F, Botling J, Nilsson K. Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells J Immunol 1993; 150: 3487–3495.Google Scholar
  109. 109.
    Brown G, Bunce CM, Rowlands DC, Williams GR. All-trans retinoic acid and 1a,25- dihydroxyvitamin D3 co-operate to promote differentiation of the human promyeloid leukemia cell line HL60 to monocytes. Leukemia 1994; 8: 806–815.PubMedGoogle Scholar
  110. 110.
    Bollag W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25dihydroxyvitamin D3, and analogs. J Cell Biochem 1994; 56: 427–435.PubMedCrossRefGoogle Scholar
  111. 111.
    Rosol TJ, Nagode LA, Couto CG, Hammer AS, Chew DJ, Peterson JL, Ayl RD, Steinmeyer CL, Capen CC. Parathyroid hormone (PTH)-related protein, PTH, and 1,25-dihydroxyvitamin D in dogs with cancer-associated hypercalcemia. Endocrinology 1992; 131: 1157–1164.PubMedCrossRefGoogle Scholar
  112. 112.
    Haq M, Kremer R, Goltzman D, Rabbani SA. A vitamin D analogue (EB 1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 1993; 91: 2416–2422.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Thomas A. Brasitus
  • Marc Bissonnette

There are no affiliations available

Personalised recommendations